The International Society for Hemodialysis (ISHD) will be live on Saturday,
October 9th, and we’ll be there!
The Physidia team is looking forward to presenting you our S3 Technology!
The growth of Home Hemodialysis (HHD) continues to remain unacceptably low. The ISHD believes that lack of awareness and proper education in the available HHD devices is a major reason for the slow growth of HHD. Increasing awareness and familiarity with the evolving and patient friendly HHD technology will increase the “comfort factor” of the nephrology community.
This ISHD event represents an important step in this direction. The Virtual SHOWCASE and EXHIBIT HALL will be a one-stop shop for all physicians, fellows, nurses, dialysis technicians, patients, and others with an interest in home hemodialysis.
We will be showcase S3 Technology to a wide audience and interact with ISHD Panelists on various features of their products – providing participants the opportunity to view all the HHD devices side-by-side in a Virtual Showcase.
- Increase awareness of available technology in HHD amongst dialysis providers to promote growth of HHD.
- Provide a unique online platform to the HHD industry to showcase the latest technology and highlight unique features of HHD devices.
- Offer a unique opportunity to the presenters, panelists and the nephrologists/nurses/technicians to interact on various aspects of HHD technology.
ISHD is a nonprofit membership society with the mission to improve care of ESKD patients; promote hemodialysis education and research; facilitate dissemination of dialysis related knowledge, and be a patient advocate in all dialysis and related matters.
Created in Angers (France) in 2011, Physidia developed and commercializes S³, the first system designed specifically for patients who need daily hemodialysis whilst ensuring their safety and comfort. This innovation is based on several technological breaking points, offering a robust, portable and connected device, whilst ensuring a treatment performed in total autonomy. The short treatment, which lasts in average 2 hours on a daily basis, can be performed at home in full autonomy without compromising the quality of the renal dialysis nor its safety. The system fully favors the patients’ social and professional reintegration, an approach which is impossible to consider for patients who must go to dialysis centers.
The company registered three patents for its hemodialysis system S³. The device and a part of the consumables are produced in France. Physidia is operating directly in France and The United Kingdom and through distributor partners in the rest of Europe. Since its origin, the principal ethos of the company has been innovation with exceptional service by providing comfort, freedom and security to every patient. http://www.physidia.com/
Renal failure and hemodialysis
End-stage renal disease (ESRD) is a severe, chronic disease impacting thousands of people in France. The conventional hemodialysis treatment (artificial kidney) implies three weekly 4-hour sessions at a healthcare facility, to which should be added waiting, recovery and transportation times.
Today representing 43,000 patients, the number of people who are given dialysis increases by 3% every year and costs around € 4bn a year to local governments. Physidia’s solution allows them to make significant economies, by reducing visits and/or transportation to healthcare centers for example.